Why the best genetically validated pain target keeps failing in the clinic: a genetic–pharmacological asymmetry at Nav1.7 (SCN9A), worked through single-cell atlases, a homeostatic-compensation model and human genetics.
bioinformatics pain reproducible-research computational-biology open-science clinvar single-cell-rna-seq human-genetics ion-channels gnomad open-targets scn9a drug-target-validation
-
Updated
Jul 1, 2026 - Jupyter Notebook